For clinicians


Quick clinical context, intended use, and how patients can get started.

Clinical overview


ProstateGuard measures the Prostate Health Index (PHI), an FDA-approved blood test analysis used as an aid in distinguishing prostate cancer from benign prostatic conditions in appropriate men (often age 50+ with PSA in a borderline range and non-suspicious DRE).


FDA Approved
  • Supports shared decision-making around biopsy
  • Can help reduce unnecessary biopsies in appropriate patients
  • Report is designed for both clinician and patient readability

Workflow

Icon 1
Patient orders ProstateGuard kit

Icon 2
Our professional will come to you to draw blood

Icon 3
Sample shipped to CLIA-certified lab for analysis

Icon 4
Patient receives report and is prompted to review next steps with their clinician

Prostate biopsy is required to confirm cancer. The test is intended as an aid—not a standalone diagnosis.

Suggested next-step pathways


Clinicians may consider repeat labs, MRI, or biopsy based on the total clinical picture (symptoms, PSA trend, family history, exam findings, and patient preference). Use your clinical judgment and local guidelines.